Background: In catheter-related candidemia, a true catheter-source infection is often difficult to distinguish from a catheter that merely marks critical illness. Our primary aim was to identify predictors of 30-day mortality; secondary aims were to characterize species-specific patterns of persistent candidemia, its prognostic meaning within the host immune–inflammatory context, and the relationship between echinocandin therapy and secondary bacterial bloodstream infection (BSI). Methods: We retrospectively reviewed 89 consecutive episodes of catheter-related candidemia at Bursa City Hospital (2021–2025). Catheter association required Candida spp. growth in concurrent catheter and peripheral blood cultures. The primary endpoint was 30-day mortality; persistent candidemia (≥72 h) and secondary bacterial BSI on days 3–30 were evaluated as exploratory endpoints. Raw MIC values were retrospectively reinterpreted according to EUCAST v12.1 breakpoints (effective 10 April 2026). Results: Thirty-day mortality was 53.9% (48/89). The multivariable model was significant (LR χ2 = 12.12, df = 4, p = 0.017; Nagelkerke R2 = 0.170); NLR was not significantly associated with mortality (OR = 1.061, 95% CI 1.00–1.13, p = 0.064). Catheter removal, initial echinocandin therapy, and persistent candidemia were not independent predictors, though catheter retention was associated with higher mortality on univariable analysis (83.3%; p = 0.033). Persistent candidemia occurred in 51.7% of episodes, most notably with C. parapsilosis and C. auris. The NLR-persistence interaction was not formally significant, but mortality was higher when both co-occurred (66.7% vs. 36.4%; OR = 3.50, p = 0.075). Secondary BSI occurred in 28.4% of episodes and was more frequent in the echinocandin group (39% vs. 20%; p = 0.062); sensitivity analyses did not change the main findings. Conclusions: Mortality could not be explained by antifungal choice alone; these findings are exploratory. Host response, source control, species distribution, survival time, and device exposure are possible contributing factors warranting evaluation in prospective studies.
31 August 2025 in Medical Journal of Western Black Sea
Aim: While intravesical Bacillus Calmette-Guérin (BCG) therapy provides successful outcomes in the treatment of non-muscle-invasive bladder cancer (NMIBC) due to its immunomodulatory effects, it can also lead to serious complications that may pose a life-threatening risk, albeit rarely. This study aimed to analyze the frequency, types, and clinical course of complications arising in patients who underwent intravesical BCG therapy in a tertiary healthcare center between 2019 and 2024. Additionally, findings that may contribute to the early recognition of these complications were examined. The obtained data are expected to aid in the effective management of BCG instillationrelated complications and enhance patient safety Material and Methods: A total of 400 patients who underwent intravesical BCG therapy were evaluated for complications using the hospital information management system. One hundred forty-six patients were excluded due to missing clinical/laboratory data or follow-ups conducted outside the center. The remaining 254 patients were assessed for demographic characteristics, comorbidities, smoking habits, Systemic Immune-Inflammation Index (SII), COVID-19 infection status, and complications related to BCG instillation. Results: The mean age of the patients was 66.2±9.7 years, and 225 (90%) were male. BCG-related complications were observed in 15 patients (6.0%). Primary disease relapse occurred in 87 patients (34.8%), and 30 patients (12.0%) died. The incidence of BCG-related complications was significantly higher in patients under 65 years of age compared to those aged 65 and older (12.0% vs. 2.5%; p=0.002). Patients without any comorbidities (p=0.022) and those without diabetes (p=0.005) had a statistically significant higher risk of developing BCG-related complications. Conclusion: This study highlights the challenges in managing complications associated with intravesical BCG therapy and underscores the importance of comprehensive patient monitoring to prevent adverse outcomes